Products Bivalirudin was commercially available as a powder for preparation of a concentrate for solution for injection or infusion (Angiox). It was approved in many countries as of 2007. It has since become unavailable. Structure and properties Bivalirudin originated from hirudin, an anticoagulant substance found in leeches. Effects Bivalirudin (ATC B01AE06) has antithrombotic properties. Indications … Bivalirudin
Products Direct oral anticoagulants (abbreviation: DOAKs) are commercially available in the form of film-coated tablets and capsules. By definition, they are oral drugs. Some representatives of the corresponding drug groups are also available as infusion preparations. Rivaroxaban (Xarelto) and dabigatran (Pradaxa) were the first active ingredients to be approved in 2008. The DOAKs were developed … DOAK
Products Dabigatran is commercially available in capsule form (Pradaxa). It has been approved in many countries since 2012. It was first approved in 2008. Structure and properties Dabigatran (C25H25N7O3, Mr = 471.5 g/mol) is present in drugs as mesilate and in the form of the prodrug dabigatran etexilate, which is metabolized in the organism by … Dabigatran
Products Direct factor Xa inhibitors are commercially available in the form of film-coated tablets and capsules. In 2008, rivaroxaban (Xarelto) was the first agent in this group to be approved in many countries and in the EU. Today, there are other drugs on the market, which are listed below. Like thrombin inhibitors, these active ingredients … Factor Xa Inhibitors
Products Dipyridamole was commercially available in many countries in the form of capsules in combination with acetylsalicylic acid (Asasantin). It had been approved in many countries since 1997. The drug is no longer marketed in many countries. Structure and properties Dipyridamole (C24H40N8O4, Mr = 504.6 g/mol) Effects Dipyridamole (ATC B01AC30) has antithrombotic properties. Indications Secondary … Dipyridamole
Products Certoparin was commercially available as a solution for injection (Sandoparin, off label). It was approved in many countries from 1989 to 2018. Structure and properties Certoparin is present in drugs as certoparin sodium. Effects Certoparin (ATC B01AB01) has antithrombotic properties. The effects are primarily due to inhibition of coagulation factor Xa by complexation with … Certoparin
Products Betrixaban was approved in the United States in 2017 in capsule form (Bevyxxa). The drug has not yet been approved in the EU (Dexxience). Structure and properties Betrixaban (C23H22ClN5O3, Mr = 451.9 g/mol) is present in the drug as betrixaban maleate. It is a pyridine and anthranilamide derivative. Effects Betrixaban has antithrombotic properties. The … Betrixaban
Products The fixed combination containing 81 mg acetylsalicylic acid and 20 mg esomeprazole was approved in many countries in June 2012 in capsule form (Axanum). In the EU, the drug has been registered since 2011. The amount of acetylsalicylic acid contained is less than in Aspirin cardio and generics, which usually contain 100 mg of … Acetylsalicylic Acid and Esomeprazole
Products Acetylsalicylic acid is commercially available in the low dosage of 100 mg in the form of enteric-coated film-coated tablets (Aspirin Cardio, generics; in Germany and Austria, Aspirin Protect). The drug has been approved in many countries since 1992. Aspirin Cardio 300 mg is also used. In the United States, drugs with 81 mg (= … Acetylsalicylic Acid 100 mg
Products Acenocoumarol is commercially available in tablet form (Sintrom, Sintrom mitis). It has been approved in many countries since 1955. Structure and properties Acenocoumarol (C19H15NO6, Mr = 353.3 g/mol) is a 4-hydroxycoumarin derivative. It is present in the drug as a racemate. Effects Acenocoumarol (ATC B01AA07) has anticoagulant and antithrombotic properties. The effects are due … Acenocoumarol
Symptoms Pulmonary arterial hypertension may initially be asymptomatic. It manifests as symptoms such as difficulty breathing that worsens with exertion, shortness of breath, fatigue, chest pain, brief loss of consciousness, cyanosis, and palpable heartbeats. Possible complications include cor pulmonale, blood clots, arrhythmias, and bleeding. Causes The condition is caused by an increase in pressure in … Pulmonary Arterial Hypertension
Products Argatroban is commercially available as a concentrate for the preparation of an infusion solution (Argatra). It was approved in many countries in 2014. Structure and properties Argatroban (C23H36N6O5S, Mr = 508.6 g/mol) is a derivative of the amino acid arginine. Effects Argatroban (ATC B01AE03) has antithrombotic properties. It inhibits fibrin formation, coagulation factor activation, … Argatroban
